Tricida (TCDA) Tops Q2 EPS by 30c

Tricida (NASDAQ: TCDA) reported Q2 EPS of ($1.16), $0.30 better than the analyst estimate of ($1.46).

“While we won’t speculate what the FDA notification may entail, we are preparing for all eventualities to swiftly resolve any potential issues. However, we remain confident in the fundamentals of veverimer and its underlying value proposition,” said Gerrit Klaerner, Ph.D., Tricida’s Chief Executive Officer and President. “I am reassured by the feedback that we have received from our Specialty Account Managers from their initial interactions with community nephrologists that confirms the unmet need to treat metabolic acidosis.”

For earnings history and earnings-related data on Tricida (TCDA) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Z Squared outlines AI power strategy and Paradox Data acquisition
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c